Oncology Institute, Inc. Quarterly Report Released - Here’s What You Should Know

The Oncology Institute, Inc. – Q2 2025 Investor Summary

Key Financial Metrics (as of and for the six months ended June 30, 2025):

• Revenue: $224.2 million (up 16% from $193.2 million in 2024)
  • Patient services: $108.96 million (+3.8% YoY)
  • Dispensary: $111.87 million (+33% YoY)
  • Clinical trials & other: $3.38 million (-19.7% YoY)
• Net Loss: $(36.59) million ((16.3)% of revenue), compared to $(35.37) million ((18.4)% of revenue) in 2024
• Loss per Share (basic & diluted): $(0.35), compared to $(0.39) in 2024
• Adjusted EBITDA: $(9.20) million, a significant improvement from $(19.65) million in 2024
• Cash & Equivalents: $30.29 million (down from $49.67 million at 12/31/24)
• Accounts Receivable: $55.66 million (up from $48.34 million at 12/31/24)
• Inventory: $15.79 million (up from $10.04 million at 12/31/24)
• Total Assets: $159.8 million
• Total Liabilities: $168.8 million
• Stockholders’ Equity (Deficit): $(8.99) million
• Long-Term Debt (net): $75.02 million (due August 2027)
• Operating Cash Flow: $(15.19) million
• Capital Expenditures: $(1.54) million
• Net Decrease in Cash: $(19.38) million from December 31, 2024

Operational Metrics:

• Clinics: 80 operating in 20 markets (down from 87 in Q2 2024)
• Lives under value-based contracts: 1.9 million (down from 2.0 million in Q2 2024)
• Oncologists and mid-level professionals: 121 across 66 clinic locations

Management Discussion & Highlights:

• Revenue Growth: Driven primarily by a 40.8% YoY increase in dispensary revenue for the quarter, mainly due to a 102.8% increase in the volume of oral drug scripts processed.
• Patient Services: Modest growth (+6.5% for the quarter) due to expansion in managed care and FFS revenue. However, as a percentage of total revenue, it declined given the rapid dispensary growth.
• Operating Expenses: Total operating expenses rose 14% YoY to $245.3 million, mainly due to higher drug costs and inventory to support increased dispensary volumes and expansion.
• SG&A: Selling, general, and administrative expenses were down 3.5% YoY, reflecting cost control efforts.
• Non-operating Expenses: Marked increase due to a $7.3 million unfavorable change in the fair value of conversion option derivative liabilities and higher interest expense from debt.
• Adjusted EBITDA Improvement: Sequential improvement primarily from topline growth and SG&A management, despite the challenging bottom line and negative operating cash flow.

Liquidity and Capital Resources:

• Cash Position: Sufficient liquidity for at least the next 12 months, though management emphasizes careful monitoring of near-term cash requirements.
• Material Cash Commitments through 2029: $127.4 million, of which $94.1 million relates to convertible note repayments (principal and interest), $32.7 million for lease commitments, and $407 thousand for other obligations.
• Debt: $85.89 million in senior secured convertible notes due August 2027; the company made $20 million in principal payments in H1 2025.
• Recent Capital Activities: $15.36 million raised through a private placement; ongoing efforts to optimize capital structure, including a new at-the-market (ATM) equity offering agreement initiated in August 2025.

Risks:

• Going Concern: While management expects sufficient liquidity for the upcoming year, reliance on variable capital sources and continued negative operating cash flow ($15.19 million YTD) present an ongoing risk.
• High Leverage: Total liabilities exceed assets, with a stockholders’ deficit of $(8.99) million and a high debt burden ($75.02 million net, due 2027).
• Revenue & Receivables Concentration: Significant dependency on a few payors. For the quarter, Payor A accounted for 13% of patient services revenue and 11% of gross receivables, and Vendor A comprised 100% of direct costs and 80% of payables, indicating vulnerability to changes in key relationships.
• Gross Margin Pressure: Costs for both oral and IV drugs increased sharply, compressing gross margins and offsetting revenue gains. Dispensary direct costs rose 31.7% YoY in the quarter.
• Regulatory and Litigation Exposure: Involvement in ordinary course legal proceedings and risks from regulatory scrutiny related to healthcare compliance (Medicare, HIPAA).
• Impairment Risk: With $7.23 million in goodwill and $12.45 million in intangibles, any significant operational or market shifts could require further writedowns.
• Operational Scaling: The net reduction in clinics and covered lives under value-based contracts points to competitive or operational headwinds in maintaining footprint and membership growth.

Conclusion: TOI demonstrated strong top-line growth, especially in dispensary operations, and made progress controlling SG&A and improving Adjusted EBITDA. Nevertheless, the company continues to face a high net loss, negative cash flow, significant debt burden, and dependency on key partners. Investors should closely monitor ongoing cash burn, efforts at capital raising, and management’s ability to sustain growth in a competitive and regulatory-sensitive environment. Further, the ATM equity program and debt structure require attention as dilution and refinancing risks persist.

Visit Publicview AI to search and analyze millions of SEC filings using AI.